
TME Pharma announces filing of patents for use of CCL2 inhibitor NOX-E36 in ophthalmology and presentation at ARVO 2025 of preclinical data showing benefit in glaucoma filtration surgery
. TME Pharma and Singapore Eye Research Institute (SERI) file new patent applications covering NOX-E36 for treatment o…